Simple Math Derails Argument Trump Has Meaningful “Stake” in Hydroxychloroquine Drugmaker

The Huffington Post deadline sure sounds damning…until you look at the math.

Donald Trump Has Stake In Hydroxychloroquine Drugmaker: Report

At least some liberals were drinking the kool-aid on this new line of attack.

Alyssa Milano declared this could even be cause for a 2nd impeachment and suggested Trump’s motivation was “personal gain.”

However a quick look at the numbers debunked this angle.

A report from Marketwatch concluded Trump’s “stake” was actually $99 to $1,485.

Considering Trump donates his entire $400k Presidential salary to charity, why exactly would he be touting a drug in hopes of multiplying this miniscule investment of $99 to $1,485 for “financial gain?”

The argument makes no sense.

Per MarketWatch, the New York Times says Trump has a “small personal stake” in Sanofi, the French drug manufacturer that produces the drug.

The report doesn’t say how small, but it notes that his three family trusts have investments in a Dodge & Cox mutual fund whose largest holding is Sanofi. A fund that matches this description is the Dodge & Cox International Stock Fund DODFX, +0.65%, which at last check was 3.3% invested in Sanofi.

Trump’s 2019 financial-disclosure form lists stakes in Family Trusts 1, 2 and 3 valued at between $1,001 and $15,000. So if Trump has the maximum $15,000 in each of the trusts, he holds a stake in Sanofi that’s worth $1,485 — and, at the minimum, just $99.

Don Jr. ridiculed the angle.